Literature DB >> 23509158

Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function.

Alexandra Mazharian1, Jun Mori, Ying-Jie Wang, Silke Heising, Benjamin G Neel, Steve P Watson, Yotis A Senis.   

Abstract

The SH2 domain-containing protein-tyrosine phosphatases Shp1 and Shp2 have been implicated in regulating signaling from a variety of platelet and megakaryocyte receptors. In this study, we investigate the functions of Shp1 and Shp2 in megakaryocytes and platelets. Megakaryocyte/platelet (MP)-specific deletion of Shp1 in mice resulted in platelets being less responsive to collagen-related peptide due to reduced GPVI expression and signaling via the Src family kinase (SFK)-Syk-PLCγ2 pathway, and fibrinogen due to reduced SFK activity. By contrast, deletion of Shp2 in the MP lineage resulted in macrothrombocytopenia and platelets being hyper-responsive to anti-CLEC-2 antibody and fibrinogen. Shp1- and Shp2-deficient megakaryocytes had partial blocks at 2N/4N ploidy; however, only the latter exhibited reduced proplatelet formation, thrombopoietin, and integrin signaling. Mice deficient in both Shp1 and Shp2 were severely macrothrombocytopenic and had reduced platelet surface glycoprotein expression, including GPVI, αIIbβ3, and GPIbα. Megakaryocytes from these mice were blocked at 2N/4N ploidy and did not survive ex vivo. Deletion of the immunoreceptor tyrosine-based inhibition motif-containing receptor G6b-B in the MP lineage phenocopied multiple features of Shp1/2-deficient mice, suggesting G6b-B is a critical regulator of Shp1 and Shp2. This study establishes Shp1 and Shp2 as major regulators of megakaryocyte development, platelet production, and function.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23509158      PMCID: PMC3656453          DOI: 10.1182/blood-2012-08-449272

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Structural basis for substrate specificity of protein-tyrosine phosphatase SHP-1.

Authors:  J Yang; Z Cheng; T Niu; X Liang; Z J Zhao; G W Zhou
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

2.  Crystal structure of human protein-tyrosine phosphatase SHP-1.

Authors:  Jian Yang; Lijun Liu; Dandan He; Xi Song; Xiaoshan Liang; Zhizhuang Joe Zhao; G Wayne Zhou
Journal:  J Biol Chem       Date:  2002-12-13       Impact factor: 5.157

3.  SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway.

Authors:  Maria I Kontaridis; Seda Eminaga; Mara Fornaro; Christina Ivins Zito; Raffaella Sordella; Jeffrey Settleman; Anton M Bennett
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

4.  Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets.

Authors:  Milenko Cicmil; Joanne M Thomas; Mireille Leduc; Cassian Bon; Jonathan M Gibbins
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

5.  The SH2 tyrosine phosphatase shp2 is required for mammalian limb development.

Authors:  T M Saxton; B G Ciruna; D Holmyard; S Kulkarni; K Harpal; J Rossant; T Pawson
Journal:  Nat Genet       Date:  2000-04       Impact factor: 38.330

6.  Evidence of a role for SHP-1 in platelet activation by the collagen receptor glycoprotein VI.

Authors:  J M Pasquet; L Quek; S Pasquet; A Poole; J R Matthews; C Lowell; S P Watson
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

7.  Platelet endothelial cell adhesion molecule-1 is a negative regulator of platelet-collagen interactions.

Authors:  K L Jones; S C Hughan; S M Dopheide; R W Farndale; S P Jackson; D E Jackson
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

8.  Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2) can play a direct role in the inhibitory function of killer cell Ig-like receptors in human NK cells.

Authors:  Sei-Ichi Yusa; Kerry S Campbell
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

9.  Convulxin binds to native, human glycoprotein Ib alpha.

Authors:  Sachiko Kanaji; Taisuke Kanaji; Kenichi Furihata; Kazunobu Kato; Jerry L Ware; Thomas J Kunicki
Journal:  J Biol Chem       Date:  2003-07-24       Impact factor: 5.157

10.  SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis.

Authors:  Christina Ivins Zito; Maria I Kontaridis; Mara Fornaro; Geng-Shen Feng; Anton M Bennett
Journal:  J Cell Physiol       Date:  2004-05       Impact factor: 6.384

View more
  30 in total

1.  Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148.

Authors:  Jun Mori; Zoltan Nagy; Giada Di Nunzio; Christopher W Smith; Mitchell J Geer; Rashid Al Ghaithi; Johanna P van Geffen; Silke Heising; Luke Boothman; Bibian M E Tullemans; Joao N Correia; Louise Tee; Marijke J E Kuijpers; Paul Harrison; Johan W M Heemskerk; Gavin E Jarvis; Alexander Tarakhovsky; Arthur Weiss; Alexandra Mazharian; Yotis A Senis
Journal:  Blood       Date:  2018-01-04       Impact factor: 22.113

Review 2.  Shp1 function in myeloid cells.

Authors:  Clare L Abram; Clifford A Lowell
Journal:  J Leukoc Biol       Date:  2017-06-12       Impact factor: 4.962

3.  G6b-B: the "Y's" and wherefores.

Authors:  Debra K Newman
Journal:  Blood       Date:  2018-09-27       Impact factor: 22.113

4.  C3G contributes to platelet activation and aggregation by regulating major signaling pathways.

Authors:  Cristina Fernández-Infante; Luis Hernández-Cano; Sara Gutiérrez-Herrero; Sara Ortiz-Rivero; Carlos Guijas; Víctor Martín-Granado; José Ramón González-Porras; Jesús Balsinde; Almudena Porras; Carmen Guerrero
Journal:  Signal Transduct Target Ther       Date:  2020-04-01

Review 5.  Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.

Authors:  Lutz Tautz; Yotis A Senis; Cécile Oury; Souad Rahmouni
Journal:  Bioorg Med Chem       Date:  2015-04-04       Impact factor: 3.641

6.  Alterations in insulin-signaling and coagulation pathways in platelets during hyperglycemia-hyperinsulinemia in healthy non-diabetic subject.

Authors:  A Koneti Rao; Robert J Freishtat; Gauthami Jalagadugula; Anamika Singh; Guangfen Mao; Andrew Wiles; Peter Cheung; Guenther Boden
Journal:  Thromb Res       Date:  2014-07-06       Impact factor: 3.944

7.  Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B.

Authors:  Timo Vögtle; Sumana Sharma; Jun Mori; Zoltan Nagy; Daniela Semeniak; Cyril Scandola; Mitchell J Geer; Christopher W Smith; Jordan Lane; Scott Pollack; Riitta Lassila; Annukka Jouppila; Alastair J Barr; Derek J Ogg; Tina D Howard; Helen J McMiken; Juli Warwicker; Catherine Geh; Rachel Rowlinson; W Mark Abbott; Anita Eckly; Harald Schulze; Gavin J Wright; Alexandra Mazharian; Klaus Fütterer; Sundaresan Rajesh; Michael R Douglas; Yotis A Senis
Journal:  Elife       Date:  2019-08-22       Impact factor: 8.140

Review 8.  Negative regulators of platelet activation and adhesion.

Authors:  L Stefanini; W Bergmeier
Journal:  J Thromb Haemost       Date:  2017-12-26       Impact factor: 5.824

9.  Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice.

Authors:  Inga Hofmann; Mitchell J Geer; Timo Vögtle; Andrew Crispin; Dean R Campagna; Alastair Barr; Monica L Calicchio; Silke Heising; Johanna P van Geffen; Marijke J E Kuijpers; Johan W M Heemskerk; Johannes A Eble; Klaus Schmitz-Abe; Esther A Obeng; Michael Douglas; Kathleen Freson; Corinne Pondarré; Rémi Favier; Gavin E Jarvis; Kyriacos Markianos; Ernest Turro; Willem H Ouwehand; Alexandra Mazharian; Mark D Fleming; Yotis A Senis
Journal:  Blood       Date:  2018-06-13       Impact factor: 22.113

10.  Paired immunoglobulin-like receptor B regulates platelet activation.

Authors:  Xuemei Fan; Panlai Shi; Jing Dai; Yeling Lu; Xue Chen; Xiaoye Liu; Kandi Zhang; Xiaolin Wu; Yueping Sun; Kemin Wang; Li Zhu; Cheng Cheng Zhang; Junfeng Zhang; Guo-Qiang Chen; Junke Zheng; Junling Liu
Journal:  Blood       Date:  2014-07-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.